Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study

Next Previous
X
Search
Trial Profile

Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Adverse reactions; Registrational
  • Acronyms PALISADE Follow-on Study
  • Sponsors Aimmune Therapeutics

    • Most Recent Events

    • 30 Jun 2022 Results presented in the Aimmune Therapeutics Media Release.
    • 30 Jun 2022 According to an Aimmune Therapeutics media release, results from an analysis to be presented on health-related quality of life (HRQoL) among patients from the Phase 3 PALISADE, ARC004 (PALISADE follow-on), ARTEMIS, RAMSES and ARC011 (RAMSES follow-on) trials will be presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress.
    • 16 Feb 2022 Results published in an Aimmune Therapeutics Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top